MP0250, an ankyrin repeat protein capable of neutralizing VEGF and HGF, effectively inhibits multiple myeloma-mediated osteolysis and myeloma cell invasion.1226 Meanwhile, MP0250 can effectively improve bortezomib efficacy without increasing toxicity, suggesting that MP0250 combined with cytotoxic therapy may be a promising therapeutic approach.1240 A phase II clinical evaluation of MP0250 in combination with bortezomib and dexamethasone in patients with multiple myeloma (NCT03136653) has been completed, although the result has not yet been disclosed. This evidence concerns the gene HGF and plasma cell myeloma.